Antimicrobial Susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016)
Abstract Background Acinetobacter calcoaceticus–A. baumannii (Acb) complex and Stenotrophomonas maltophilia represent frequent causes of hospital-acquired infections. We evaluated the frequency and resistance rates of Acb complex and S. maltophilia isolates from medical centers enrolled in the SENTR...
Uloženo v:
| Vydáno v: | Open forum infectious diseases Ročník 6; číslo Supplement_1; s. S34 - S46 |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
US
Oxford University Press
01.03.2019
|
| Témata: | |
| ISSN: | 2328-8957, 2328-8957 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Abstract
Background
Acinetobacter calcoaceticus–A. baumannii (Acb) complex and Stenotrophomonas maltophilia represent frequent causes of hospital-acquired infections. We evaluated the frequency and resistance rates of Acb complex and S. maltophilia isolates from medical centers enrolled in the SENTRY Program.
Methods
A total of 13 752 Acb complex and 6467 S. maltophilia isolates were forwarded to a monitoring laboratory by 259 participating sites from the Asia-Pacific region, Latin America, Europe, and North America between 1997 and 2016. Confirmation of species identification and antimicrobial susceptibility testing were performed using conventional methods and/or matrix-assisted laser desorption ionization–time of flight mass spectrometry and the broth microdilution method, respectively. Antimicrobial susceptibility results were interpreted by CLSI and EUCAST 2018 criteria.
Results
Acb complex and S. maltophilia were most frequently isolated from patients hospitalized with pneumonia (42.9% and 55.8%, respectively) and bloodstream infections (37.3% and 33.8%, respectively). Colistin and minocycline were the most active agents against Acb complex (colistin MIC50/90, ≤0.5/2 mg/L; 95.9% susceptible) and S. maltophilia (minocycline MIC50/90, ≤1/2 mg/L; 99.5% susceptible) isolates, respectively. Important temporal decreases in susceptibility rates among Acb complex isolates were observed for all antimicrobial agents in all regions. Rates of extensively drug-resistant Acb complex rates were highest in Europe (66.4%), followed by Latin America (61.5%), Asia-Pacific (56.9%), and North America (38.8%). Among S. maltophilia isolates, overall trimethoprim-sulfamethoxazole (TMP-SMX) susceptibility rates decreased from 97.2% in 2001–2004 to 95.7% in 2013–2016, but varied according to the geographic region.
Conclusions
We observed important reductions of susceptibility rates to all antimicrobial agents among Acb complex isolates obtained from all geographic regions. In contrast, resistance rates to TMP-SMX among S. maltophilia isolates remained low and relatively stable during the study period. |
|---|---|
| AbstractList | Abstract
Background
Acinetobacter calcoaceticus–A. baumannii (Acb) complex and Stenotrophomonas maltophilia represent frequent causes of hospital-acquired infections. We evaluated the frequency and resistance rates of Acb complex and S. maltophilia isolates from medical centers enrolled in the SENTRY Program.
Methods
A total of 13 752 Acb complex and 6467 S. maltophilia isolates were forwarded to a monitoring laboratory by 259 participating sites from the Asia-Pacific region, Latin America, Europe, and North America between 1997 and 2016. Confirmation of species identification and antimicrobial susceptibility testing were performed using conventional methods and/or matrix-assisted laser desorption ionization–time of flight mass spectrometry and the broth microdilution method, respectively. Antimicrobial susceptibility results were interpreted by CLSI and EUCAST 2018 criteria.
Results
Acb complex and S. maltophilia were most frequently isolated from patients hospitalized with pneumonia (42.9% and 55.8%, respectively) and bloodstream infections (37.3% and 33.8%, respectively). Colistin and minocycline were the most active agents against Acb complex (colistin MIC50/90, ≤0.5/2 mg/L; 95.9% susceptible) and S. maltophilia (minocycline MIC50/90, ≤1/2 mg/L; 99.5% susceptible) isolates, respectively. Important temporal decreases in susceptibility rates among Acb complex isolates were observed for all antimicrobial agents in all regions. Rates of extensively drug-resistant Acb complex rates were highest in Europe (66.4%), followed by Latin America (61.5%), Asia-Pacific (56.9%), and North America (38.8%). Among S. maltophilia isolates, overall trimethoprim-sulfamethoxazole (TMP-SMX) susceptibility rates decreased from 97.2% in 2001–2004 to 95.7% in 2013–2016, but varied according to the geographic region.
Conclusions
We observed important reductions of susceptibility rates to all antimicrobial agents among Acb complex isolates obtained from all geographic regions. In contrast, resistance rates to TMP-SMX among S. maltophilia isolates remained low and relatively stable during the study period. Background Acinetobacter calcoaceticus–A. baumannii (Acb) complex and Stenotrophomonas maltophilia represent frequent causes of hospital-acquired infections. We evaluated the frequency and resistance rates of Acb complex and S. maltophilia isolates from medical centers enrolled in the SENTRY Program. Methods A total of 13 752 Acb complex and 6467 S. maltophilia isolates were forwarded to a monitoring laboratory by 259 participating sites from the Asia-Pacific region, Latin America, Europe, and North America between 1997 and 2016. Confirmation of species identification and antimicrobial susceptibility testing were performed using conventional methods and/or matrix-assisted laser desorption ionization–time of flight mass spectrometry and the broth microdilution method, respectively. Antimicrobial susceptibility results were interpreted by CLSI and EUCAST 2018 criteria. Results Acb complex and S. maltophilia were most frequently isolated from patients hospitalized with pneumonia (42.9% and 55.8%, respectively) and bloodstream infections (37.3% and 33.8%, respectively). Colistin and minocycline were the most active agents against Acb complex (colistin MIC50/90, ≤0.5/2 mg/L; 95.9% susceptible) and S. maltophilia (minocycline MIC50/90, ≤1/2 mg/L; 99.5% susceptible) isolates, respectively. Important temporal decreases in susceptibility rates among Acb complex isolates were observed for all antimicrobial agents in all regions. Rates of extensively drug-resistant Acb complex rates were highest in Europe (66.4%), followed by Latin America (61.5%), Asia-Pacific (56.9%), and North America (38.8%). Among S. maltophilia isolates, overall trimethoprim-sulfamethoxazole (TMP-SMX) susceptibility rates decreased from 97.2% in 2001–2004 to 95.7% in 2013–2016, but varied according to the geographic region. Conclusions We observed important reductions of susceptibility rates to all antimicrobial agents among Acb complex isolates obtained from all geographic regions. In contrast, resistance rates to TMP-SMX among S. maltophilia isolates remained low and relatively stable during the study period. Acinetobacter calcoaceticus-A. baumannii (Acb) complex and Stenotrophomonas maltophilia represent frequent causes of hospital-acquired infections. We evaluated the frequency and resistance rates of Acb complex and S. maltophilia isolates from medical centers enrolled in the SENTRY Program.BACKGROUNDAcinetobacter calcoaceticus-A. baumannii (Acb) complex and Stenotrophomonas maltophilia represent frequent causes of hospital-acquired infections. We evaluated the frequency and resistance rates of Acb complex and S. maltophilia isolates from medical centers enrolled in the SENTRY Program.A total of 13 752 Acb complex and 6467 S. maltophilia isolates were forwarded to a monitoring laboratory by 259 participating sites from the Asia-Pacific region, Latin America, Europe, and North America between 1997 and 2016. Confirmation of species identification and antimicrobial susceptibility testing were performed using conventional methods and/or matrix-assisted laser desorption ionization-time of flight mass spectrometry and the broth microdilution method, respectively. Antimicrobial susceptibility results were interpreted by CLSI and EUCAST 2018 criteria.METHODSA total of 13 752 Acb complex and 6467 S. maltophilia isolates were forwarded to a monitoring laboratory by 259 participating sites from the Asia-Pacific region, Latin America, Europe, and North America between 1997 and 2016. Confirmation of species identification and antimicrobial susceptibility testing were performed using conventional methods and/or matrix-assisted laser desorption ionization-time of flight mass spectrometry and the broth microdilution method, respectively. Antimicrobial susceptibility results were interpreted by CLSI and EUCAST 2018 criteria.Acb complex and S. maltophilia were most frequently isolated from patients hospitalized with pneumonia (42.9% and 55.8%, respectively) and bloodstream infections (37.3% and 33.8%, respectively). Colistin and minocycline were the most active agents against Acb complex (colistin MIC50/90, ≤0.5/2 mg/L; 95.9% susceptible) and S. maltophilia (minocycline MIC50/90, ≤1/2 mg/L; 99.5% susceptible) isolates, respectively. Important temporal decreases in susceptibility rates among Acb complex isolates were observed for all antimicrobial agents in all regions. Rates of extensively drug-resistant Acb complex rates were highest in Europe (66.4%), followed by Latin America (61.5%), Asia-Pacific (56.9%), and North America (38.8%). Among S. maltophilia isolates, overall trimethoprim-sulfamethoxazole (TMP-SMX) susceptibility rates decreased from 97.2% in 2001-2004 to 95.7% in 2013-2016, but varied according to the geographic region.RESULTSAcb complex and S. maltophilia were most frequently isolated from patients hospitalized with pneumonia (42.9% and 55.8%, respectively) and bloodstream infections (37.3% and 33.8%, respectively). Colistin and minocycline were the most active agents against Acb complex (colistin MIC50/90, ≤0.5/2 mg/L; 95.9% susceptible) and S. maltophilia (minocycline MIC50/90, ≤1/2 mg/L; 99.5% susceptible) isolates, respectively. Important temporal decreases in susceptibility rates among Acb complex isolates were observed for all antimicrobial agents in all regions. Rates of extensively drug-resistant Acb complex rates were highest in Europe (66.4%), followed by Latin America (61.5%), Asia-Pacific (56.9%), and North America (38.8%). Among S. maltophilia isolates, overall trimethoprim-sulfamethoxazole (TMP-SMX) susceptibility rates decreased from 97.2% in 2001-2004 to 95.7% in 2013-2016, but varied according to the geographic region.We observed important reductions of susceptibility rates to all antimicrobial agents among Acb complex isolates obtained from all geographic regions. In contrast, resistance rates to TMP-SMX among S. maltophilia isolates remained low and relatively stable during the study period.CONCLUSIONSWe observed important reductions of susceptibility rates to all antimicrobial agents among Acb complex isolates obtained from all geographic regions. In contrast, resistance rates to TMP-SMX among S. maltophilia isolates remained low and relatively stable during the study period. ( ) complex and represent frequent causes of hospital-acquired infections. We evaluated the frequency and resistance rates of complex and isolates from medical centers enrolled in the SENTRY Program. A total of 13 752 complex and 6467 isolates were forwarded to a monitoring laboratory by 259 participating sites from the Asia-Pacific region, Latin America, Europe, and North America between 1997 and 2016. Confirmation of species identification and antimicrobial susceptibility testing were performed using conventional methods and/or matrix-assisted laser desorption ionization-time of flight mass spectrometry and the broth microdilution method, respectively. Antimicrobial susceptibility results were interpreted by CLSI and EUCAST 2018 criteria. complex were most frequently isolated from patients hospitalized with pneumonia (42.9% and 55.8%, respectively) and bloodstream infections (37.3% and 33.8%, respectively). Colistin and minocycline were the most active agents against complex (colistin MIC , ≤0.5/2 mg/L; 95.9% susceptible) and (minocycline MIC , ≤1/2 mg/L; 99.5% susceptible) isolates, respectively. Important temporal decreases in susceptibility rates among complex isolates were observed for all antimicrobial agents in all regions. Rates of extensively drug-resistant complex rates were highest in Europe (66.4%), followed by Latin America (61.5%), Asia-Pacific (56.9%), and North America (38.8%). Among isolates, overall trimethoprim-sulfamethoxazole (TMP-SMX) susceptibility rates decreased from 97.2% in 2001-2004 to 95.7% in 2013-2016, but varied according to the geographic region. We observed important reductions of susceptibility rates to all antimicrobial agents among complex isolates obtained from all geographic regions. In contrast, resistance rates to TMP-SMX among isolates remained low and relatively stable during the study period. |
| Author | Gales, Ana C Gur, Deniz Seifert, Harald Castanheira, Mariana Sader, Helio S Jones, Ronald N |
| AuthorAffiliation | 1 Universidade Federal de São Paulo, São Paulo, Brazil 4 Hacettepe University, Ankara, Turkey 5 JMI Laboratories, North Liberty, Iowa 3 German Centre for Infection Research, partner site Bonn-Cologne, Germany 2 Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany |
| AuthorAffiliation_xml | – name: 2 Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany – name: 4 Hacettepe University, Ankara, Turkey – name: 1 Universidade Federal de São Paulo, São Paulo, Brazil – name: 5 JMI Laboratories, North Liberty, Iowa – name: 3 German Centre for Infection Research, partner site Bonn-Cologne, Germany |
| Author_xml | – sequence: 1 givenname: Ana C surname: Gales fullname: Gales, Ana C email: ana.gales@gmail.com organization: Universidade Federal de São Paulo, São Paulo, Brazil – sequence: 2 givenname: Harald surname: Seifert fullname: Seifert, Harald organization: Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany – sequence: 3 givenname: Deniz surname: Gur fullname: Gur, Deniz organization: Hacettepe University, Ankara, Turkey – sequence: 4 givenname: Mariana surname: Castanheira fullname: Castanheira, Mariana organization: JMI Laboratories, North Liberty, Iowa – sequence: 5 givenname: Ronald N surname: Jones fullname: Jones, Ronald N organization: JMI Laboratories, North Liberty, Iowa – sequence: 6 givenname: Helio S surname: Sader fullname: Sader, Helio S organization: JMI Laboratories, North Liberty, Iowa |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30895213$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks9rFDEUxwep2Fp78i4BQVpkNcnM7Ew8CMvSaqGodOvBU8hkMt1XMnljkinurf-D_51H_xKzbC3tgl7yg_d533xf3nua7Th0JsueM_qGUZG_xQ7atKy4yB9lezzn9aQWZbVz77ybHYRwRSlljJa0Ek-y3ZymAGf5XvZr5iL0oD02oCxZjEGbIUIDFuKKYEdmGpyJ2CgdjSdaWY1Kmwh6DL9vfj6MNmrslXMAZI79YM0PolxLFtE4jB6HJfboVCC9sjHd0hOKzC04SKrkNKBV0YR35NyE0cZATjz2JC4NWRx_ujj_Rrad-msD1iqnDfni8dKrnhwyIapki1M2PXqWPe6UDebgdt_Pvp4cX8w_Ts4-fzidz84muqTTOKl1UauO646ylomynra0ZNwUtOWqoU2tWWGaoq7Kik9rXrai6DpRCc21aUtR0Hw_e7_RHcamN602Lnpl5eChV34lUYF8GHGwlJd4LadFskvrJHB4K-Dx-2hClD2kNqxrMzgGyZMtXpaplQl9uYVe4ehdKk_mrKKiqIpaJOrFfUd3Vv62PQGvN0D6zRC86e4QRuV6ruR6ruRmrhLNtmgNUUXAdTlg_5HzapOD4_Bf8T_7XuaE |
| CitedBy_id | crossref_primary_10_1093_jacamr_dlac040 crossref_primary_10_1128_aac_00781_22 crossref_primary_10_1186_s13756_020_00750_5 crossref_primary_10_1002_phar_2828 crossref_primary_10_1128_cmr_00093_24 crossref_primary_10_22207_JPAM_17_4_06 crossref_primary_10_1016_j_ijantimicag_2023_106878 crossref_primary_10_1093_jac_dkaa208 crossref_primary_10_3390_antibiotics14030274 crossref_primary_10_1002_jcb_30424 crossref_primary_10_1128_aac_00124_25 crossref_primary_10_1007_s11908_019_0706_5 crossref_primary_10_3390_antibiotics11091263 crossref_primary_10_1038_s41579_024_01054_w crossref_primary_10_1128_AAC_02375_19 crossref_primary_10_1016_j_ajic_2024_04_184 crossref_primary_10_1080_14787210_2024_2440018 crossref_primary_10_1016_j_jgar_2023_02_018 crossref_primary_10_1099_jmm_0_001655 crossref_primary_10_1007_s40121_024_01099_7 crossref_primary_10_1016_j_jiac_2019_12_010 crossref_primary_10_3390_antibiotics11121711 crossref_primary_10_1038_s41429_024_00801_8 crossref_primary_10_1016_j_jgar_2021_05_001 crossref_primary_10_1128_JCM_00654_21 crossref_primary_10_3390_antibiotics13090875 crossref_primary_10_1089_mdr_2022_0279 crossref_primary_10_1097_MCC_0000000000000755 crossref_primary_10_1128_spectrum_01143_22 crossref_primary_10_1016_j_ajic_2022_08_012 crossref_primary_10_1007_s42770_022_00706_4 crossref_primary_10_1089_mdr_2020_0602 crossref_primary_10_1128_AAC_01264_21 crossref_primary_10_1128_CMR_00030_19 crossref_primary_10_3201_eid2812_220347 crossref_primary_10_3390_antibiotics10101226 crossref_primary_10_3390_microorganisms10030506 crossref_primary_10_3390_pathogens12050743 crossref_primary_10_1128_JCM_01094_21 crossref_primary_10_3390_antibiotics11030378 crossref_primary_10_3390_antibiotics12071198 crossref_primary_10_1099_jmm_0_001029 crossref_primary_10_1128_AAC_00071_20 crossref_primary_10_1007_s42770_025_01669_y crossref_primary_10_1128_aac_00139_22 crossref_primary_10_1186_s12866_025_03914_8 crossref_primary_10_1016_j_drudis_2021_07_001 crossref_primary_10_1016_j_jbiotec_2022_04_006 crossref_primary_10_3390_antibiotics12050910 crossref_primary_10_1016_j_ijantimicag_2025_107597 crossref_primary_10_1002_phar_2447 crossref_primary_10_1128_AAC_00739_21 crossref_primary_10_1128_AAC_00793_21 crossref_primary_10_1080_14787210_2019_1685875 crossref_primary_10_1093_ofid_ofaa141 crossref_primary_10_1128_AAC_00297_20 crossref_primary_10_1093_jac_dkaa020 crossref_primary_10_1371_journal_pone_0298577 crossref_primary_10_1128_AAC_01433_20 crossref_primary_10_4103_jmedsci_jmedsci_261_22 crossref_primary_10_1093_ajhp_zxab451 crossref_primary_10_3390_microbiolres15040175 crossref_primary_10_1007_s11033_024_09979_4 crossref_primary_10_1128_spectrum_00542_22 crossref_primary_10_3389_fmicb_2019_01689 crossref_primary_10_1016_j_infpip_2025_100443 crossref_primary_10_1002_phar_2950 crossref_primary_10_1093_ofid_ofae458 crossref_primary_10_1128_AAC_02631_20 crossref_primary_10_1016_j_scitotenv_2020_138232 crossref_primary_10_1038_s41598_022_15386_1 crossref_primary_10_1128_aac_00505_23 crossref_primary_10_3390_antibiotics13060553 crossref_primary_10_1007_s42770_023_01015_0 crossref_primary_10_3390_v15030673 crossref_primary_10_1093_cid_ciad109 crossref_primary_10_1080_22221751_2021_1976080 crossref_primary_10_1371_journal_ppat_1010308 crossref_primary_10_1002_phar_2908 crossref_primary_10_3389_fphar_2023_1222044 crossref_primary_10_1186_s12879_021_07024_4 crossref_primary_10_3389_fcimb_2023_1266295 crossref_primary_10_1128_spectrum_01981_23 crossref_primary_10_1186_s13568_022_01491_x crossref_primary_10_31362_patd_1142048 crossref_primary_10_1016_j_ijantimicag_2024_107410 crossref_primary_10_1128_spectrum_01379_25 crossref_primary_10_2147_IDR_S357344 crossref_primary_10_1016_j_jhin_2019_09_001 crossref_primary_10_1128_AAC_01397_21 crossref_primary_10_1093_jac_dkae168 crossref_primary_10_5812_jjm_94647 crossref_primary_10_1093_ofid_ofaa083 crossref_primary_10_1128_aac_00426_23 crossref_primary_10_1186_s13756_021_00909_8 crossref_primary_10_1016_j_jiph_2024_03_007 crossref_primary_10_1371_journal_pone_0244751 crossref_primary_10_1128_AAC_01154_19 crossref_primary_10_1093_ofid_ofac095 crossref_primary_10_4103_ijmr_IJMR_9_19 crossref_primary_10_1515_abm_2020_0026 crossref_primary_10_1016_S0992_5945_22_00188_X crossref_primary_10_3390_antibiotics11111457 crossref_primary_10_26453_otjhs_1058819 crossref_primary_10_1007_s10096_022_04525_1 crossref_primary_10_1093_femspd_ftad022 crossref_primary_10_1186_s13756_021_00888_w crossref_primary_10_1128_AAC_00788_19 crossref_primary_10_3389_fmicb_2023_1271733 crossref_primary_10_1093_jacamr_dlad049 crossref_primary_10_1186_s13104_019_4344_7 crossref_primary_10_3390_pathogens10081006 crossref_primary_10_1016_j_jgar_2022_02_001 crossref_primary_10_1097_QCO_0000000000000975 crossref_primary_10_3389_fmicb_2020_01160 crossref_primary_10_1128_spectrum_01509_24 crossref_primary_10_3389_fcimb_2024_1390053 crossref_primary_10_3389_fcimb_2023_1325379 crossref_primary_10_1093_ofid_ofae140 crossref_primary_10_3390_microorganisms12122477 crossref_primary_10_1128_AAC_01506_19 crossref_primary_10_1016_j_cmi_2019_04_013 crossref_primary_10_1016_S0140_6736_24_02081_6 crossref_primary_10_7759_cureus_76483 crossref_primary_10_3389_fmicb_2022_869653 crossref_primary_10_1007_s42770_024_01461_4 crossref_primary_10_1016_j_idnow_2021_01_014 crossref_primary_10_1128_aac_01086_24 crossref_primary_10_1016_j_jmii_2020_12_012 crossref_primary_10_1128_spectrum_03757_23 crossref_primary_10_1016_j_micpath_2023_106233 crossref_primary_10_1186_s13104_021_05567_y crossref_primary_10_1128_spectrum_02712_21 crossref_primary_10_1080_14787210_2024_2412637 crossref_primary_10_1128_AAC_00559_20 crossref_primary_10_3390_pathogens9070522 crossref_primary_10_1128_aac_01865_24 crossref_primary_10_4103_aam_aam_141_23 crossref_primary_10_1038_s41429_019_0188_6 crossref_primary_10_1093_cid_ciz824 crossref_primary_10_1097_MD_0000000000021051 crossref_primary_10_1099_ijsem_0_005018 crossref_primary_10_3389_fmicb_2020_584603 crossref_primary_10_1093_jambio_lxaf204 crossref_primary_10_1099_jmm_0_001594 crossref_primary_10_1007_s00253_023_12594_1 crossref_primary_10_1016_j_ijregi_2025_100698 crossref_primary_10_1186_s13756_024_01376_7 |
| Cites_doi | 10.1128/CMR.00058-07 10.6061/clinics/2013(04)21 10.1099/ijs.0.000043 10.1093/jac/dkv456 10.1086/648455 10.1016/j.jhin.2012.02.008 10.1007/s00520-017-4032-x 10.1128/AAC.48.2.666-669.2004 10.1007/s00134-015-4079-4 10.1038/nrmicro1789 10.1128/AAC.04808-14 10.1128/JCM.35.11.2819-2825.1997 10.1128/AAC.01324-13 10.1016/j.jhin.2006.06.025 10.3201/eid1304.061378 10.2217/fmb.09.84 10.1089/mdr.2014.0176 10.1128/JCM.30.10.2680-2685.1992 10.1016/j.jiac.2014.10.009 10.1093/jac/dkx322 10.1093/jac/dkw327 10.1093/jac/dkn009 10.1128/JCM.35.6.1394-1397.1997 10.1016/j.diagmicrobio.2015.08.006 10.1128/JCM.00988-08 10.1017/ice.2016.174 10.1586/14787210.2015.1025055 10.1093/jac/dki182 10.2217/fmb.09.45 10.1099/jmm.0.2008/002469-0 10.1093/cid/ciu613 10.1016/j.ijantimicag.2012.09.008 10.1007/s40121-017-0153-2 10.1128/AAC.03930-14 10.1128/CMR.00058-16 10.3201/eid1301.060716 10.1111/j.1469-0691.2009.02770.x 10.1099/ijsem.0.001318 10.1086/430790 10.1128/AAC.01682-13 10.1093/jac/dkn434 10.1086/340055 10.1016/j.ijantimicag.2004.08.013 10.1038/nrd3957-c1 10.1093/jac/dkh128 10.3346/jkms.2013.28.1.62 10.1093/jac/dkl499 10.1097/00005792-197703000-00001 10.1128/AAC.48.5.1586-1592.2004 10.1093/jac/dkp428 10.1093/jac/dks084 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2019 The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2019 – notice: The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | TOX AAYXX CITATION NPM 3V. 7X7 7XB 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM |
| DOI | 10.1093/ofid/ofy293 |
| DatabaseName | Oxford Journals Open Access Collection CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Public Health Database (ProQuest) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Public Health ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Global Surveillance of Antimicrobial Resistance: 20 Years of Experience with the SENTRY Program |
| EISSN | 2328-8957 |
| EndPage | S46 |
| ExternalDocumentID | PMC6419908 30895213 10_1093_ofid_ofy293 10.1093/ofid/ofy293 |
| Genre | Journal Article |
| GeographicLocations | North America Europe Latin America |
| GeographicLocations_xml | – name: Latin America – name: North America – name: Europe |
| GroupedDBID | 0R~ 53G 5VS AAFWJ AAMVS AAPPN AAPXW AAVAP ABDBF ABPTD ABXVV ACGFS ADBBV ADHZD ADPDF ADRAZ AENZO AFPKN AFULF ALMA_UNASSIGNED_HOLDINGS ALUQC AOIJS BAWUL BAYMD BCNDV BTTYL CIDKT DIK EBS EJD GROUPED_DOAJ H13 HYE IAO KQ8 KSI M48 M~E O9- OAWHX OJQWA OK1 OVD OVEED PEELM ROL ROX RPM TEORI TJX TOX 7X7 8C1 8FI 8FJ AAYXX ABEJV ABGNP ABUWG ACUHS AFFHD AFKRA AMNDL BENPR CCPQU CITATION FYUFA HMCUK IHR ITC PHGZM PHGZT PIMPY PJZUB PPXIY UKHRP NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c506t-8c48af2cf01d19586d0512e40d2ab0b8c14eb4875726825d94ff979c2ced59403 |
| IEDL.DBID | 8C1 |
| ISICitedReferencesCount | 156 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000510176800005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2328-8957 |
| IngestDate | Tue Nov 04 01:55:30 EST 2025 Fri Sep 05 14:30:42 EDT 2025 Tue Oct 07 07:03:11 EDT 2025 Wed Feb 19 02:27:28 EST 2025 Sat Nov 29 05:40:13 EST 2025 Tue Nov 18 20:26:00 EST 2025 Wed Aug 28 03:19:25 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Supplement_1 |
| Keywords | multidrug resistance gram-negative bacilli surveillance nonfermentative carbapenem resistant |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com http://creativecommons.org/licenses/by-nc-nd/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c506t-8c48af2cf01d19586d0512e40d2ab0b8c14eb4875726825d94ff979c2ced59403 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/3170947489?pq-origsite=%requestingapplication% |
| PMID | 30895213 |
| PQID | 3170947489 |
| PQPubID | 7089189 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6419908 proquest_miscellaneous_2195255957 proquest_journals_3170947489 pubmed_primary_30895213 crossref_primary_10_1093_ofid_ofy293 crossref_citationtrail_10_1093_ofid_ofy293 oup_primary_10_1093_ofid_ofy293 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-03-01 |
| PublicationDateYYYYMMDD | 2019-03-01 |
| PublicationDate_xml | – month: 03 year: 2019 text: 2019-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | US |
| PublicationPlace_xml | – name: US – name: United States – name: Oxford |
| PublicationTitle | Open forum infectious diseases |
| PublicationTitleAlternate | Open Forum Infect Dis |
| PublicationYear | 2019 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | Kwon (2020081004070345000_CIT0011) 2007; 59 Oliveira (2020081004070345000_CIT0046) 2013; 68 Vasconcelos (2020081004070345000_CIT0050) 2015; 83 Nemec (2020081004070345000_CIT0031) 2015; 65 Glew (2020081004070345000_CIT0001) 1977; 56 Penwell (2020081004070345000_CIT0043) 2015; 59 Castanheira (2020081004070345000_CIT0037) 2008; 46 Fritsche (2020081004070345000_CIT0040) 2005; 41(Suppl 4) Lashinsky (2020081004070345000_CIT0042) 2017; 6 Garnacho-Montero (2020081004070345000_CIT0045) 2015; 41 Toleman (2020081004070345000_CIT0026) 2007; 13 Gerner-Smidt (2020081004070345000_CIT0033) 1992; 30 Higgins (2020081004070345000_CIT0047) 2004; 48 Wang (2020081004070345000_CIT0053) 2014; 58 Valdezate (2020081004070345000_CIT0055) 2005; 56 Weiner (2020081004070345000_CIT0048) 2016; 37 Ritchie (2020081004070345000_CIT0041) 2014; 59(Suppl 6) Cho (2020081004070345000_CIT0054) 2014; 58 David (2020081004070345000_CIT0015) 2008; 61 CLSI. M07Ed11E (2020081004070345000_CIT0029) 2018 Seifert (2020081004070345000_CIT0006) 1997; 35 Wong (2020081004070345000_CIT0004) 2017; 30 Sanchez (2020081004070345000_CIT0056) 2009; 4 (2020081004070345000_CIT0030) 2018 Sader (2020081004070345000_CIT0039) 2005; 25 Dexter (2020081004070345000_CIT0007) 2015; 13 Hand (2020081004070345000_CIT0022) 2016; 71 Robenshtok (2020081004070345000_CIT0009) 2006; 64 Velázquez-Acosta (2020081004070345000_CIT0019) 2018; 26 Kaur (2020081004070345000_CIT0024) 2015; 21 Chang (2020081004070345000_CIT0018) Mendes (2020081004070345000_CIT0034) 2009; 63 Jacobson (2020081004070345000_CIT0059) 2016; 71 Cosgaya (2020081004070345000_CIT0032) 2016; 66 CLSI. M100Ed28E (2020081004070345000_CIT0028) 2018 Esposito (2020081004070345000_CIT0058) Rizek (2020081004070345000_CIT0023) 2015; 21 Wood (2020081004070345000_CIT0044) 2002; 34 Falagas (2020081004070345000_CIT0027) 2009; 4 Higgins (2020081004070345000_CIT0012) 2010; 65 Nowak (2020081004070345000_CIT0017) 2017; 72 Da Silva (2020081004070345000_CIT0013) Mendes (2020081004070345000_CIT0036) 2009; 15 Hejnar (2020081004070345000_CIT0014) 1999; 142 Gur (2020081004070345000_CIT0035) 2008; 57 Castanheira (2020081004070345000_CIT0038) 2014; 58 Sanchez (2020081004070345000_CIT0057) Peleg (2020081004070345000_CIT0005) 2008; 21 Barbolla (2020081004070345000_CIT0025) 2004; 48 Chung (2020081004070345000_CIT0052) 2013; 28 Cai (2020081004070345000_CIT0016) 2012; 67 Dijkshoorn (2020081004070345000_CIT0002) 2007; 5 Tseng (2020081004070345000_CIT0020) 2009; 30 Wendt (2020081004070345000_CIT0008) 1997; 35 Nicodemo (2020081004070345000_CIT0021) 2004; 53 Zarrilli (2020081004070345000_CIT0049) 2013; 41 Garazi (2020081004070345000_CIT0051) 2012; 81 Spellberg (2020081004070345000_CIT0003) 2013; 12 Sunenshine (2020081004070345000_CIT0010) 2007; 13 |
| References_xml | – volume: 21 start-page: 538 year: 2008 ident: 2020081004070345000_CIT0005 article-title: Acinetobacter baumannii: emergence of a successful pathogen publication-title: Clin Microbiol Rev doi: 10.1128/CMR.00058-07 – volume: 68 start-page: 569 year: 2013 ident: 2020081004070345000_CIT0046 article-title: The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin/sulbactam publication-title: Clinics (Sao Paulo) doi: 10.6061/clinics/2013(04)21 – volume: 65 start-page: 934 year: 2015 ident: 2020081004070345000_CIT0031 article-title: Acinetobacter seifertii sp. nov., a member of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolated from human clinical specimens publication-title: Int J Syst Evol Microbiol doi: 10.1099/ijs.0.000043 – volume: 71 start-page: 1071 year: 2016 ident: 2020081004070345000_CIT0022 article-title: Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkv456 – volume: 30 start-page: 1193 year: 2009 ident: 2020081004070345000_CIT0020 article-title: Risk factors for mortality in patients with nosocomial Stenotrophomonas maltophilia pneumonia publication-title: Infect Control Hosp Epidemiol doi: 10.1086/648455 – volume: 81 start-page: 114 year: 2012 ident: 2020081004070345000_CIT0051 article-title: Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review publication-title: J Hosp Infect doi: 10.1016/j.jhin.2012.02.008 – volume: 26 start-page: 1953 year: 2018 ident: 2020081004070345000_CIT0019 article-title: Stenotrophomonas maltophilia bacteremia and pneumonia at a tertiary-care oncology center: a review of 16 years publication-title: Support Care Cancer doi: 10.1007/s00520-017-4032-x – volume: 48 start-page: 666 year: 2004 ident: 2020081004070345000_CIT0025 article-title: Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.48.2.666-669.2004 – volume: 41 start-page: 2057 year: 2015 ident: 2020081004070345000_CIT0045 article-title: Task force on management and prevention of Acinetobacter baumannii infections in the ICU publication-title: Intensive Care Med doi: 10.1007/s00134-015-4079-4 – volume: 5 start-page: 939 year: 2007 ident: 2020081004070345000_CIT0002 article-title: An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii publication-title: Nat Rev Microbiol doi: 10.1038/nrmicro1789 – volume: 59 start-page: 1680 year: 2015 ident: 2020081004070345000_CIT0043 article-title: Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.04808-14 – volume: 35 start-page: 2819 year: 1997 ident: 2020081004070345000_CIT0006 article-title: Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods publication-title: J Clin Microbiol doi: 10.1128/JCM.35.11.2819-2825.1997 – volume: 58 start-page: 176 year: 2014 ident: 2020081004070345000_CIT0053 article-title: Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01324-13 – volume: 64 start-page: 282 year: 2006 ident: 2020081004070345000_CIT0009 article-title: The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes publication-title: J Hosp Infect doi: 10.1016/j.jhin.2006.06.025 – ident: 2020081004070345000_CIT0013 article-title: Insights on the horizontal gene transfer of carbapenemase determinants in the opportunistic pathogen Acinetobacter baumannii publication-title: Microorganisms – volume: 13 start-page: 559 year: 2007 ident: 2020081004070345000_CIT0026 article-title: Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes publication-title: Emerg Infect Dis doi: 10.3201/eid1304.061378 – volume: 4 start-page: 1103 year: 2009 ident: 2020081004070345000_CIT0027 article-title: Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature publication-title: Future Microbiol doi: 10.2217/fmb.09.84 – volume: 21 start-page: 380 year: 2015 ident: 2020081004070345000_CIT0024 article-title: Distribution of class 1 integrons, sul1 and sul2 genes among clinical isolates of Stenotrophomonas maltophilia from a tertiary care hospital in north India publication-title: Microb Drug Resist doi: 10.1089/mdr.2014.0176 – volume: 30 start-page: 2680 year: 1992 ident: 2020081004070345000_CIT0033 article-title: Ribotyping of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex publication-title: J Clin Microbiol doi: 10.1128/JCM.30.10.2680-2685.1992 – ident: 2020081004070345000_CIT0057 article-title: Overexpression of the efflux pumps SmeVWX and SmeDEF is a major cause of resistance to co-trimoxazole in Stenotrophomonas maltophilia publication-title: Antimicrob Agents Chemother – volume: 21 start-page: 114 year: 2015 ident: 2020081004070345000_CIT0023 article-title: In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives publication-title: J Infect Chemother doi: 10.1016/j.jiac.2014.10.009 – volume: 72 start-page: 3277 year: 2017 ident: 2020081004070345000_CIT0017 article-title: High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkx322 – ident: 2020081004070345000_CIT0018 article-title: Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options publication-title: Front Microbiol – volume: 71 start-page: 3620 year: 2016 ident: 2020081004070345000_CIT0059 article-title: Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkw327 – ident: 2020081004070345000_CIT0058 article-title: Evolution of Stenotrophomonas maltophilia in cystic fibrosis lung over chronic infection: a genomic and phenotypic population study publication-title: Front Microbiol – volume: 61 start-page: 962 year: 2008 ident: 2020081004070345000_CIT0015 article-title: Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkn009 – volume: 35 start-page: 1394 year: 1997 ident: 2020081004070345000_CIT0008 article-title: Survival of Acinetobacter baumannii on dry surfaces publication-title: J Clin Microbiol doi: 10.1128/JCM.35.6.1394-1397.1997 – volume: 83 start-page: 382 year: 2015 ident: 2020081004070345000_CIT0050 article-title: The changing epidemiology of Acinetobacter spp. producing OXA carbapenemases causing bloodstream infections in Brazil: a BrasNet report publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2015.08.006 – volume: 46 start-page: 3179 year: 2008 ident: 2020081004070345000_CIT0037 article-title: Emergence and clonal dissemination of OXA-24- and OXA-58-producing Acinetobacter baumannii strains in Houston, Texas: report from the SENTRY Antimicrobial Surveillance Program publication-title: J Clin Microbiol doi: 10.1128/JCM.00988-08 – volume: 37 start-page: 1288 year: 2016 ident: 2020081004070345000_CIT0048 article-title: Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014 publication-title: Infect Control Hosp Epidemiol doi: 10.1017/ice.2016.174 – volume: 13 start-page: 567 year: 2015 ident: 2020081004070345000_CIT0007 article-title: Community-acquired Acinetobacter baumannii: clinical characteristics, epidemiology and pathogenesis publication-title: Expert Rev Anti Infect Ther doi: 10.1586/14787210.2015.1025055 – volume: 56 start-page: 220 year: 2005 ident: 2020081004070345000_CIT0055 article-title: Preservation of topoisomerase genetic sequences during in vivo and in vitro development of high-level resistance to ciprofloxacin in isogenic Stenotrophomonas maltophilia strains publication-title: J Antimicrob Chemother doi: 10.1093/jac/dki182 – volume: 4 start-page: 655 year: 2009 ident: 2020081004070345000_CIT0056 article-title: Stenotrophomonas maltophilia drug resistance publication-title: Future Microbiol doi: 10.2217/fmb.09.45 – volume: 57 start-page: 1529 year: 2008 ident: 2020081004070345000_CIT0035 article-title: Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites publication-title: J Med Microbiol doi: 10.1099/jmm.0.2008/002469-0 – volume: 59(Suppl 6) start-page: S374 year: 2014 ident: 2020081004070345000_CIT0041 article-title: A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections publication-title: Clin Infect Dis doi: 10.1093/cid/ciu613 – volume: 41 start-page: 11 year: 2013 ident: 2020081004070345000_CIT0049 article-title: Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2012.09.008 – volume: 6 start-page: 199 year: 2017 ident: 2020081004070345000_CIT0042 article-title: Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii: a review publication-title: Infect Dis Ther doi: 10.1007/s40121-017-0153-2 – volume: 142 start-page: 73 year: 1999 ident: 2020081004070345000_CIT0014 article-title: Characteristics of Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of beta-lactamases) isolated from haemocultures from patients at the teaching hospital in Olomouc publication-title: Acta Univ Palacki Olomuc Fac Med – volume-title: Performance Standards for Antimicrobial Susceptibility Testing: 28th Informational Supplement. year: 2018 ident: 2020081004070345000_CIT0028 – volume: 58 start-page: 7358 year: 2014 ident: 2020081004070345000_CIT0038 article-title: Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel β-lactamases, GES-22 and VIM-35 publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.03930-14 – volume: 30 start-page: 409 year: 2017 ident: 2020081004070345000_CIT0004 article-title: Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges publication-title: Clin Microbiol Rev doi: 10.1128/CMR.00058-16 – volume: 13 start-page: 97 year: 2007 ident: 2020081004070345000_CIT0010 article-title: Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization publication-title: Emerg Infect Dis doi: 10.3201/eid1301.060716 – volume: 15 start-page: 588 year: 2009 ident: 2020081004070345000_CIT0036 article-title: Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy publication-title: Clin Microbiol Infect doi: 10.1111/j.1469-0691.2009.02770.x – volume: 66 start-page: 4105 year: 2016 ident: 2020081004070345000_CIT0032 article-title: Acinetobacter dijkshoorniae sp. nov., a member of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex mainly recovered from clinical samples in different countries publication-title: Int J Syst Evol Microbiol doi: 10.1099/ijsem.0.001318 – volume: 41(Suppl 4) start-page: S276 year: 2005 ident: 2020081004070345000_CIT0040 article-title: Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program publication-title: Clin Infect Dis doi: 10.1086/430790 – volume: 58 start-page: 581 year: 2014 ident: 2020081004070345000_CIT0054 article-title: Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01682-13 – volume: 63 start-page: 55 year: 2009 ident: 2020081004070345000_CIT0034 article-title: Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia Pacific nations: report from the SENTRY Surveillance Program publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkn434 – year: 2018 ident: 2020081004070345000_CIT0030 – volume: 34 start-page: 1425 year: 2002 ident: 2020081004070345000_CIT0044 article-title: Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia publication-title: Clin Infect Dis doi: 10.1086/340055 – volume: 25 start-page: 57 year: 2005 ident: 2020081004070345000_CIT0039 article-title: Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY antimicrobial surveillance program publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2004.08.013 – volume: 12 start-page: 963 year: 2013 ident: 2020081004070345000_CIT0003 article-title: The value of single-pathogen antibacterial agents publication-title: Nat Rev Drug Discov doi: 10.1038/nrd3957-c1 – volume: 53 start-page: 604 year: 2004 ident: 2020081004070345000_CIT0021 article-title: In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, etest and agar dilution methods publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkh128 – volume: 28 start-page: 62 year: 2013 ident: 2020081004070345000_CIT0052 article-title: Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates publication-title: J Korean Med Sci doi: 10.3346/jkms.2013.28.1.62 – volume: 59 start-page: 525 year: 2007 ident: 2020081004070345000_CIT0011 article-title: Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkl499 – volume: 56 start-page: 79 year: 1977 ident: 2020081004070345000_CIT0001 article-title: Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies publication-title: Medicine (Baltimore) doi: 10.1097/00005792-197703000-00001 – volume: 48 start-page: 1586 year: 2004 ident: 2020081004070345000_CIT0047 article-title: In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.48.5.1586-1592.2004 – volume: 65 start-page: 233 year: 2010 ident: 2020081004070345000_CIT0012 article-title: Global spread of carbapenem-resistant Acinetobacter baumannii publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkp428 – volume: 67 start-page: 1607 year: 2012 ident: 2020081004070345000_CIT0016 article-title: Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies publication-title: J Antimicrob Chemother doi: 10.1093/jac/dks084 – volume-title: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard year: 2018 ident: 2020081004070345000_CIT0029 |
| SSID | ssj0001105079 |
| Score | 2.513562 |
| Snippet | Abstract
Background
Acinetobacter calcoaceticus–A. baumannii (Acb) complex and Stenotrophomonas maltophilia represent frequent causes of hospital-acquired... ( ) complex and represent frequent causes of hospital-acquired infections. We evaluated the frequency and resistance rates of complex and isolates from medical... Background Acinetobacter calcoaceticus–A. baumannii (Acb) complex and Stenotrophomonas maltophilia represent frequent causes of hospital-acquired infections.... Acinetobacter calcoaceticus-A. baumannii (Acb) complex and Stenotrophomonas maltophilia represent frequent causes of hospital-acquired infections. We evaluated... |
| SourceID | pubmedcentral proquest pubmed crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | S34 |
| SubjectTerms | Antimicrobial agents Nosocomial infections Supplement |
| Title | Antimicrobial Susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016) |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30895213 https://www.proquest.com/docview/3170947489 https://www.proquest.com/docview/2195255957 https://pubmed.ncbi.nlm.nih.gov/PMC6419908 |
| Volume | 6 |
| WOSCitedRecordID | wos000510176800005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: M~E dateStart: 20140101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVASL databaseName: Oxford Journals Open Access Collection customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: TOX dateStart: 20140101 isFulltext: true titleUrlDefault: https://academic.oup.com/journals/ providerName: Oxford University Press – providerCode: PRVPQU databaseName: Health & Medical Collection (ProQuest) customDbUrl: eissn: 2328-8957 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: 7X7 dateStart: 20140401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central Database Suite (ProQuest) customDbUrl: eissn: 2328-8957 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: BENPR dateStart: 20140401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (ProQuest) customDbUrl: eissn: 2328-8957 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: 8C1 dateStart: 20140401 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2328-8957 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: PIMPY dateStart: 20140401 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF7RFiEuvAuBEhapB0Cyun7EXnNBoUpEDw1REqT0ZO3LqiXHDrZT0Rv_gX_HkV_CjO2kTYV64WJptWN7pJ2ZndmZ_YaQQyfk0vFjYbmCSQvRCC3pGs-yjRQeD23OhK6bTQSjEZ_Pw3F74Fa2ZZVrm1gbap0rPCM_gn0OIhHESvm0_G5h1yjMrrYtNHbInu0wDxWTH9tXZyzgPLAgbK_lQex-BAum4XHphO7WRrR1ue2aj3mzVPLa3jN8-L9cPyIPWq-T9hsxeUzumOwJuXfa5tWfkt_9rEoWSQ3KBHTTVVlXu9SFs5c0j2kf6VD3EduZwrqqXCi8_7gq__z8tT0rBSYGsiShaGxS84OKTNMpOOd5VeTL8xyYEiVdiBRBDeAXgrbopCk9AVVA7_cjnZhylVYlHRb5goKXSqeD0WxyRm9yWlwYbJwEskvHTa0ZfYdlLcAWeB3--2fk23AwO_5itV0fLNVjfmVx5XEROypmtkYkHF-D3XCMx7QjJJNc2Z6RGGYFjg_hrQ69OA6DUDnK6F7oMXef7GZ5Zl4QquETgVTwZgCBEPZPZL1YaiAWDheCdciHtQhEqoVEx84cadSk5t0I5SVq5KVDDjfEywYJ5N9kb0CWbqc4WMtK1BqMMroSlA55u5kGVcf8jchMvioj2Fx6GAH2gg553ojl5j8u4zBpw8eDLYHdECCM-PZMlpzXcOK-B6vC-Mvb2XpF7sOqhU353QHZrYqVeU3uqosqKYsu2QnmQf3k3VoHu2Tv82A0nnTrQw4YjU9Ox2cwmn2d_wWIH0jO |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1fb9MwELfGQMAL__8UBjPSkAApmuukcYyEUAWrVm2rprVI5Sk4tqNFapPSpIO-8R34HnwgHvkk3CVpt05ob3vgJS--OJZ9d76Lf_4dIVtcBhH3Y-W4ikUOshE6kWs9p2kj5QWyGTBlymITotcLhkN5uEZ-Le7CIKxy4RNLR20yjf_It2Gfg0wEuVLeT746WDUKT1cXJTQqtdiz82-QsuXvuh9hfV9y3tkZfNh16qoCjm4xv3AC7QUq5jpmTYNMK74BveTWY4ariEWBbno2wjBecB_SJyO9OJZCaq6taUmPudDvFXIV_LhACJkYitN_OhCsMCHra4BMutugIAYecy7dlY1v5TLdmZj2PDTzzF7Xuf2_zdIdcquOqmm7MoO7ZM2m98j1gxo3cJ_8bqdFMk5K0imQ68_yEs1TAoPnNItpG-XQtyF3NQW91ZnSeL9zlv_58XO1NVJ48JEmCUVnOrLfqUoN7UPykRXTbHKcwSSonI7VCEkb4BOK1uyrI9oFU8fo_i09svlsVOS0M83GFKJw2t_pDY4-0_MjnZ5YLAwFtkkPKywdfYWwHRgWRFX-6wfk06XM7EOynmapfUyogS5EpOFNAYke1odkrTgyIKx4oBRrkDcLlQt1TfmOlUdGYQU9cEPUz7DSzwbZWgpPKqaTf4ttgu5eLLGx0M2wdoh5eKqYDfJi2QyuDM-nVGqzWR7C5tnCDLclGuRRZQbL77gsgMYmdC5WDGQpgDTpqy1pclzSpfserAoLnlw8rE1yY3dwsB_ud3t7T8lNWEFZQQ03yHoxndln5Jo-KZJ8-ry0eUq-XLb5_AWDA52G |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antimicrobial+Susceptibility+of+Acinetobacter+calcoaceticus-Acinetobacter+baumannii+Complex+and+Stenotrophomonas+maltophilia+Clinical+Isolates%3A+Results+From+the+SENTRY+Antimicrobial+Surveillance+Program+%281997-2016%29&rft.jtitle=Open+forum+infectious+diseases&rft.au=Gales%2C+Ana+C&rft.au=Seifert%2C+Harald&rft.au=Gur%2C+Deniz&rft.au=Castanheira%2C+Mariana&rft.date=2019-03-01&rft.issn=2328-8957&rft.eissn=2328-8957&rft.volume=6&rft.issue=Suppl+1&rft.spage=S34&rft_id=info:doi/10.1093%2Fofid%2Fofy293&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2328-8957&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2328-8957&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2328-8957&client=summon |